



## Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,  
Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website. : www.fermentabiotech.com



F.No.: 908

August 12, 2025

Corporate Relations

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai – 400 001

Dear Sir,

**Sub: Outcome of Board Meeting and Unaudited Financial Results - Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

**Ref: Scrip Code 506414**

We write to inform you that the Board of Directors of the Company at its meeting held on August 12, 2025 has, *inter alia*, approved unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025 as enclosed.

We are enclosing herewith the Limited Review Reports on the aforesaid results (Standalone and Consolidated) dated August 12, 2025 issued by the Statutory Auditors, SRBC & Co. LLP, Chartered Accountants.

Kindly take the above on record.

The Board meeting commenced at 11:30 a.m. (IST) and concluded at 12.45 p.m. (IST).

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

**Varadvinayak Khambete**

Company Secretary & Head - Legal

Membership No. A33861

Encl: As above

Factory : Village Takoli, P.O. Nagwain,  
Dist. Mandi - 175 121, Himachal Pradesh, India.  
Tel. : +91-1905-287246 / 48 / 49  
Fax: +91-1905-287250  
Email: info@fermentabiotech.com  
Website: www.fermentabiotech.com

Factory : Z - 109 B & C, SEZ II, Dahej,  
Taluka - Vagara, Dist: Bharuch - 392  
130,  
Gujarat, India.  
Tel. : +91-2641-291440 / 444  
Email: info@fermentabiotech.com  
Website: www.fermentabiotech.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Fermenta Biotech Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Fermenta Biotech Limited (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP  
Chartered Accountants  
ICAI Firm registration number: 324982E/E300003

*Poonam Tadarwal*

per Poonam Tadarwal  
Partner  
Membership No.: 136454  
UDIN: 25136454BMOJWN7909  
Mumbai, Maharashtra  
12 August 2025





**Fermenta Biotech Limited**  
CIN:L99999MH1951PLC008485

Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.  
Tel:+91-22-67980888, Fax:+91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025					
₹ in Lakhs					
Sr. No.	Particulars	Standalone			
		Quarter Ended		Year Ended	
		Unaudited	Audited	Unaudited	Audited
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
			(Note 6)		
1	<b>Income</b>				
	a) Revenue from operations (refer note 4)	11,901.87	12,203.79	7,269.77	43,053.17
	b) Other income	884.08	388.30	262.75	1,167.78
2	<b>Total Income (a+b)</b>	12,785.95	12,592.09	7,532.52	44,220.95
3	<b>Expenses</b>				
	a) Cost of materials consumed	2,942.90	3,540.20	2,700.91	12,898.28
	b) Purchases of stock-in-trade	536.38	716.84	143.08	1,723.68
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	908.90	(35.16)	(218.82)	(758.96)
	d) Employee benefits expense (refer note 5)	1,897.28	1,558.77	1,454.70	6,009.69
	e) Finance costs	310.50	298.96	342.33	1,419.92
	f) Depreciation and amortisation expense	554.73	559.74	586.49	2,317.29
	g) Other expenses	3,363.34	3,155.79	3,008.86	13,169.01
	<b>Total expenses (a to g)</b>	10,514.03	9,795.14	8,017.55	36,778.91
4	<b>Profit before Exceptional Items and tax (2-3)</b>	2,271.92	2,796.95	(485.03)	7,442.04
5	Exceptional Items	-	-	-	-
6	<b>Profit/(Loss) after Exceptional Items and before tax (4-5)</b>	2,271.92	2,796.95	(485.03)	7,442.04
7	<b>Tax expense</b>				
	a) Current tax	400.38	497.57	-	1,312.24
	b) Deferred tax charge / (credit)	248.16	(631.74)	-	(631.74)
	<b>Total tax expense (a+b)</b>	648.54	(134.17)	-	680.50
8	<b>Profit/(Loss) for the period/year after tax (6-7)</b>	1,623.38	2,931.12	(485.03)	6,761.54
9	<b>Other Comprehensive Income</b>				
	(A) i) Items that will not be reclassified to Profit or Loss	-	(112.48)	-	(112.48)
	ii) Income tax thereon	-	32.75	-	32.75
	(B) Items that will be reclassified to Profit or Loss (net of tax)	6.82	1.37	0.96	5.26
	<b>Total other comprehensive Income/(Loss)</b>	6.82	(78.36)	0.96	(74.47)
10	<b>Total Comprehensive Income/(Loss) for the period/year (8+9)</b>	1,630.20	2,852.76	(484.07)	6,687.07
11	Paid-up equity share capital (Face value ₹ 5/- per share)	1,458.45	1,458.45	1,444.70	1,458.45
12	Other equity (excluding revaluation reserve)				36,536.78
13	<b>Earnings per equity share of ₹ 5 each (not annualised)</b>				
	Earnings per equity share of ₹ 5 each				
	a) ₹ Basic	5.57	10.05	(1.68)	23.18
	b) ₹ Diluted	5.56	10.05	(1.68)	23.18
	See accompanying notes to the Standalone financial results				

SIGNED FOR IDENTIFICATION  
BY  
SRBC & CO LLP  
MUMBAI



## NOTES:

1. Segment Information		₹ in Lakhs			
Particulars	Standalone				
	Quarter Ended			Year Ended	
	Unaudited	Audited	Unaudited	Audited	
	June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025	
	(Note 6)				
Segment revenue					
- Bulk drugs/chemicals	11,672.43	10,555.77	7,007.24	36,140.13	
- Property (Refer Note 4)	355.22	1,089.57	246.98	5,440.18	
- Unallocated	758.30	946.75	278.30	2,640.64	
Total Income	12,785.95	12,592.09	7,532.52	44,220.95	
Segment results					
- Bulk drugs/chemicals	2,215.45	2,043.98	(115.25)	3,843.96	
- Property	156.95	936.84	109.38	4,830.10	
- Unallocated (Net)	210.02	115.09	(136.83)	187.90	
Total Profit / (loss) before tax and finance cost	2,582.42	3,095.91	(142.70)	8,861.96	
- Finance costs	(310.50)	(298.96)	(342.33)	(1,419.92)	
Total Profit / (loss) before tax	2,271.92	2,796.95	(485.03)	7,442.04	
Segment Assets					
- Bulk Drugs/chemicals	48,884.19	50,546.97	45,700.65	50,546.97	
- Property	1,791.39	1,306.54	1,238.49	1,306.54	
- Unallocated	12,288.72	10,393.05	7,276.25	10,393.05	
Total Segment Assets	62,964.30	62,246.56	54,215.39	62,246.56	
Segment Liabilities					
- Bulk Drugs/chemicals	8,024.86	8,832.67	7,312.34	8,832.67	
- Property	4,193.29	3,879.84	4,150.77	3,879.84	
- Unallocated	11,052.53	11,538.82	11,797.07	11,538.82	
Total Segment Liabilities	23,270.68	24,251.33	23,260.18	24,251.33	

SIGNED FOR IDENTIFICATION  
BY

41

S R B C & CO LLP  
MUMBAI



2

- 2 The above unaudited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 12th August, 2025. The results of the Company are available for investors at [www.fermentabiotech.com](http://www.fermentabiotech.com) and [www.bseindia.com](http://www.bseindia.com).
- 3 These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the previous year the Company had sold part of its Investment in Property consisting of commercial property in Ceejay House, Worli, Mumbai and part of freehold land located at Village Takawe. In the current year the company has further sold part of its Investment in freehold land located at Village Takawe and accordingly income on sale of such property for the quarter ended June 30, 2025 is ₹ 162.89 lakhs, (for the quarter ended March 31, 2025 is ₹ 856.23 lakhs, for the quarter ended June 30, 2024 is ₹ Nil and the year ended March 31, 2025 is ₹ 4457.88 lakhs). Such income has been recognised under the head 'Revenue from operations' pertaining to property segment.
- 5 In the Current quarter ended June 30, 2025 254,590 Stock option have been granted under the Company's ESOP Scheme.
- 6 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and the unaudited published year to date figures upto the nine months ended December 31, 2024 financial year which were subjected to a limited review by the statutory auditors.

Place: Thane  
Date : 12th August 2025



Prashant Nagre  
Managing Director  
DIN:09165447



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Fermenta Biotech Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Fermenta Biotech Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its associate for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S. No.	Name of the Entity	Relationship
1	Fermenta Biotech Limited	Parent Company
2	Fermenta Biotech (UK) Limited	Subsidiary
3	Fermenta Biotech GmbH	Subsidiary
4	Fermenta Biotech USA LLC	Subsidiary
5	Fermenta USA LLC	Subsidiary
6	Fermenta Environment Solutions Private Limited	Subsidiary
7	Health and Wellness India Private Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.





6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:

- 2 subsidiaries whose unaudited interim financial results include total revenues of Rs 1,711.80 lakhs, total net loss after tax of Rs. 71.09 lakhs, total comprehensive loss of Rs. 71.09 lakhs, for the quarter ended June 30, 2025, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

- 2 subsidiaries, whose interim financial results and other financial information reflect total revenues of NIL, total net profit after tax of Rs. 2.11 lakhs total comprehensive income of Rs. 2.11 lakhs, for the quarter ended June 30, 2025.
- 1 associate, whose interim financial results includes the Group's share of total revenues of Rs. Nil, net profit of Rs. Nil and Group's share of total comprehensive loss of Rs. Nil, for the quarter ended June 30, 2025

The unaudited interim financial results and other unaudited financial information of the above subsidiaries and associate have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries and associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

*Poonam Tadarwal*

per Poonam Tadarwal  
Partner

Membership No.: 136454  
UDIN: 25136454BMOJW05261  
Mumbai, Maharashtra  
August 12, 2025





Fermenta Biotech Limited  
CIN:L99999MH1951PLC008485  
Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.  
Tel:+91-22-67980888, Fax:+91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025					₹ in Lakhs
Sr. No.	Particulars	Consolidated			
		Quarter Ended		Year Ended	
		Unaudited	Audited	Unaudited	Audited
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		(Note 6)			
1	Income				
	a) Revenue from operations (refer note 4)	13,626.27	13,984.81	7,813.17	46,947.73
	b) Other income	877.13	389.39	281.78	1,181.85
2	Total Income (a+b)	14,503.40	14,374.20	8,094.95	48,129.58
3	Expenses				
	a) Cost of materials consumed	2,257.20	5,049.44	2,719.22	11,890.53
	b) Purchases of stock-in-trade	1,562.21	1,987.48	417.61	5,965.61
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	884.88	(2,023.52)	(217.54)	(3,116.09)
	d) Employee benefits expense (refer note 5)	2,035.00	1,688.73	1,577.57	6,510.43
	e) Finance costs	310.50	299.09	343.22	1,419.20
	f) Depreciation and amortisation expense	581.23	586.47	612.28	2,421.83
	g) Other expenses	4,063.67	3,588.34	3,235.89	14,717.29
	Total expenses (a to g)	11,694.69	11,176.03	8,688.25	39,808.80
4	Profit/(Loss) before Exceptional Items and tax (2-3)	2,808.71	3,198.17	(593.30)	8,320.78
5	Exceptional Items	-	-	-	-
6	Profit/(Loss) after Exceptional Items and before tax (4-5)	2,808.71	3,198.17	(593.30)	8,320.78
7	Tax expense				
	a) Current tax	400.38	497.57	-	1,312.24
	b) Deferred tax charge / (credit)	248.16	(631.74)	-	(631.74)
	Total tax expense (a+b)	648.54	(134.17)	-	680.50
8	Profit/(Loss) for the period after tax but before share of profit/(loss) of an associate(6-7)	2,160.17	3,332.34	(593.30)	7,640.28
9	Share of profit / (loss) of an associate	-	-	-	-
10	Net Profit/(Loss) after tax (8-9)	2,160.17	3,332.34	(593.30)	7,640.28
11	Attributable to:				
	- Owners of the parent	2,183.49	3,438.96	(581.90)	7,686.18
	- Non-controlling interests	(23.32)	(106.62)	(11.40)	(45.90)
12	Other Comprehensive Income				
	Items that will not be reclassified to Profit or Loss				
	i) Remeasurements of defined benefit plan	-	(112.48)	-	(112.48)
	ii) Income tax thereon	-	32.75	-	32.75
	Items that will be reclassified to Profit or Loss				
	i) Exchange differences in translating the financials statements of foreign exchange	(273.11)	(133.93)	30.46	(116.11)
	ii) Net fair value change in investment in equity instruments through other comprehensive income (net)	6.82	1.37	0.96	5.26
	Total other comprehensive Income/(Loss)	(266.29)	(212.29)	31.42	(190.58)
13	Total Comprehensive Income/(Loss) for the period/year (10+12)	1,893.88	3,120.05	(561.88)	7,449.70
	Attributable to:				
	- Owners of the parent .	1,917.20	3,226.67	(550.48)	7,495.60
	- Non-controlling interests .	(23.32)	(106.62)	(11.40)	(45.90)
14	Paid-up equity share capital (Face value ₹ 5/- per share)	1,458.45	1,458.45	1,444.70	1,458.45
15	Other equity (excluding revaluation reserve)	-	-	-	34,808.77
16	Earnings per equity share of ₹ 5 each (not annualised)				
	Earnings per equity share of ₹ 5 each				
	a) ₹ Basic	7.49	11.79	(2.01)	26.35
	b) ₹ Diluted	7.47	11.79	(2.01)	26.35
	See accompanying notes to the Consolidated financial results				

SIGNED FOR IDENTIFICATION  
BY  
S R B C & CO LLP  
MUMBAI





**NOTES:**

1. Segment Information		₹ in Lakhs			
Particulars	Consolidated				
	Quarter Ended			Year Ended	
	Unaudited	Audited	Unaudited	Audited	
	June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025	
		(Note 6)			
Segment revenue					
- Bulk drugs/chemicals	13,389.89	12,337.89	7,569.67	40,048.76	
- Property (Refer Note 4)	355.22	1,089.57	246.98	5,440.18	
- Unallocated	758.29	946.74	278.30	2,640.64	
Total Income	14,503.40	14,374.20	8,094.95	48,129.58	
Segment results					
- Bulk drugs/chemicals	2,752.23	2,445.26	(222.66)	4,722.32	
- Property	156.95	936.84	109.38	4,830.10	
- Unallocated (Net)	210.03	115.16	(136.80)	187.56	
Total Profit / (loss) before tax and finance cost	3,119.21	3,497.26	(250.08)	9,739.98	
- Finance costs	(310.50)	(299.09)	(343.22)	(1,419.20)	
Total Profit / (loss) before tax	2,808.71	3,198.17	(593.30)	8,320.78	
Segment Assets					
- Bulk drugs/chemicals	48,694.99	49,747.88	43,964.36	49,747.88	
- Property	1,791.39	1,306.54	1,238.49	1,306.54	
- Unallocated	12,288.72	10,393.11	7,284.56	10,393.11	
Total Segment Assets	62,775.10	61,447.53	52,487.41	61,447.53	
Segment Liabilities					
- Bulk drugs/chemicals	9,715.69	10,177.29	8,571.53	10,177.29	
- Property	4,193.29	3,879.84	4,150.77	3,879.84	
- Unallocated	11,049.24	11,538.88	11,805.35	11,538.88	
Total Segment Liabilities	24,958.22	25,596.01	24,527.65	25,596.01	

SIGNED FOR IDENTIFICATION  
BY   
S R B C & CO LLP  
MUMBAI



28

- 2 The above unaudited consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 12th August, 2025. The results of the Company are available for investors at [www.fermentabiotech.com](http://www.fermentabiotech.com) and [www.bseindia.com](http://www.bseindia.com).
- 3 These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the previous year the parent Company had sold part of its Investment in Property consisting of commercial property in Ceejay House, Worli, Mumbai and part of freehold land located at Village Takawe. In current year the parent company has further sold part of its Investment in freehold land located at Village Takawe and accordingly income on sale of such property for the quarter ended June 30, 2025 is ₹ 162.89 lakhs, (for the quarter ended March 31, 2025 is ₹ 856.23 lakhs, for the quarter ended June 30, 2024 is ₹ Nil) and the year ended March 31, 2025 is ₹ 4457.88 lakhs). Such income has been recognised under the head 'Revenue from operations' pertaining to property segment.
- 5 In the Current quarter ended June 30, 2025 254,590 Stock option have been granted under the parent company's ESOP Scheme.
- 6 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and the unaudited published year to date figures upto the nine months ended December 31, 2024 financial year which were subjected to a limited review by the statutory auditors.

Place: Thane  
Date : 12th August 2025



  
Prashant Nagre  
Managing Director  
DIN-09165447

